Over the last few decades the life sciences industry players viz. Pharmaceuticals, Biopharmaceuticals, Nutraceuticals have put in lot of efforts in research and are continuously implementing advanced technologies in their research workflows to bring about improvements in reducing the time taken for a molecule to reach the patients bedside as a drug. The process still remains a costly affair due to the level of complexities involved in experimentation and time-consuming screening processes with no guarantee of success.
On an average it takes close to 10 years for a molecule from the discovery lab to reach the markets as a drug at an estimated spend of close to USD 2 - 2.5 billion. Considering a scenario where the drug has to be recalled due to regulatory concerns or during clinical trials then the losses accrued are huge as the statistics state only 12% of drugs which enter clinical trial phase are actually receiving approvals to be released into the markets.
The life science industry has opened up its doors to technology though cautiously but steadily to address the bottlenecks in their research processes so that they can risk an early failure than a failure in the later stage of discovery. Computational Drug Designing techniques have been vastly employed to get better insights into their candidate identification processes, adsorption, distribution, metabolism and excretion profiles of a drug in the human body.